RTOG Foundation, a non-profit organization which conducts clinical trials designed to discover more effective cancer therapies, recently opened a new trial RTOG 3523, also known as the “MOMENTUM-1” study, testing the radioactive drug [177Lu]Lu-DOTA-TATE (hereafter referred to as 177Lu-Dotatate) in adult who have progressive intracranial grade 1-3 meningioma.
The MOMENTUM-1 study is a multicenter, randomized, and open-label phase II trial aiming to enroll approximately 153 patients in this population. Enrolled patients will be randomly assigned 2:1 to receive either 177Lu-Dotatate or best standard of care medical therapy, including bevacizumab, hydroxyurea, everolimus, sunitinib. If patients on the standard of care treatment arm experience disease progression, they will be able to cross over to the 177Lu-Dotatate treatment arm. The RTOG 3523 study investigators are trying to determine if treatment with 177Lu-Dotatate improves progression-free survival for patients compared to the typical medical treatment for meningioma.
“Meningiomas are the most common primary intracranial tumors and, while many of these tumors are considered benign and can be removed by surgery, a subset of patients have aggressively growing tumors and experience frequent recurrence following repeated surgical resection and/or radiation. For these patients, there are no good treatment options, and chemotherapy is typically ineffective at managing or eradicating these tumors,” stated Erik P. Sulman, MD, PhD, at the New York University Grossman School of Medicine and the Radiation Oncology Principal Investigator of the MOMENTUM-1 study.
“There remains an urgent need to find an effective treatment option for patients with advanced and repeatedly progressive intracranial meningioma. The MOMENTUM-1 study has the ability to establish and define a new standard of care for this patient population,” added Sylvia C. Kurz, MD, PhD , at the Yale University School of Medicine and the Neuro-Oncology Principal Investigator of the MOMENTUM-1 study.
More information regarding the RTOG 3523 MOMENTUM-1 study can be found on the RTOG Foundation website.
About RTOG Foundation
The RTOG Foundation is a nonprofit organization dedicated to improving outcomes for cancer patients through the conduct of practice changing clinical trials. RTOGF collaborates with partners from industry and federally funded programs to support its research. RTOGF is the successor of the National Cancer Institute (NCI)-funded Radiation Therapy Oncology group that was organized in 1968 as a national clinical cooperative group for the purpose of conducting multicenter radiation therapy research and clinical investigations. It was part of the NCI-funded cooperative group program and managed by the American College of Radiology (ACR) from 1971 until 2014. During that time, it activated over 500 protocols, accrued more than 110,000 patients to cooperative group studies, and published over 1,000 papers reporting the results of its findings. RTOGF has continued its close relationship with ACR to engage in clinical trial research collaborations with a variety of industry partners and participates in Federal grant-funded research through its leadership in the NCI National Clinical Trial Network group NRG Oncology. www.RTOG.org